Registry of adult patients with immune thrombocytopenia and autoimmune hemolytic anemia in France
Official title: French Registry of Adult Patients With Immune Thrombocytopenia and Autoimmune Hemolytic Anemia
Run by University Hospital, Toulouse · NCT02877706 · Data updated 2026-11-12
This study is collecting information from adults in France who have recently been diagnosed with immune thrombocytopenia or autoimmune hemolytic anemia to better understand these conditions and how well different treatments work in real life.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 1500 (estimated) |
| Sponsor | University Hospital, Toulouse Academic / other |
| Drugs / interventions | FOSFAMATINIB |
| Locations | 1 site (Toulouse) |
| Status | Recruiting |
| Started | June 2013 |
| Main results expected | December 2026 |
| Study ends | December 2029 |
| Registry record updated | December 31, 2025 |
| Trial ID | NCT02877706 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this registry are adults aged 18 and older who have recently been diagnosed with ITP or AIHA.
✕Probably not a fit
Patients who oppose data collection will not benefit from this registry.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The CARMEN registry is a national observational study that collects data on adult patients newly diagnosed with Immune Thrombocytopenia (ITP) or Autoimmune Hemolytic Anemia (AIHA) in France. It aims to describe the clinical features of these conditions, evaluate the real-world risk-benefit ratio of various treatments, and assess adherence to management guidelines. By gathering comprehensive data, the registry seeks to improve understanding and management of ITP and AIHA in clinical practice.
Why it matters
Potential benefit: If successful, this registry could enhance treatment strategies and outcomes for patients with ITP and AIHA.
How similar studies have gone: Similar registries have shown success in improving patient outcomes and treatment adherence in other conditions, indicating a promising approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * adult patients (18+ year-old) * newly diagnosed for ITP/AIHA or initiation of FOSFAMATINIB Exclusion criteria: \- opposition to data collection
Where it's running
-
Service de Médecine Interne
Toulouse, France Recruiting
Study contacts
- Principal investigator: Moulis Guillaume, MD PhD — University Hopsital Toulouse
- Study coordinator: Moulis Guillaume, MD PhD
- Email: moulis.g@chu-toulouse.fr
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
National cohort for pediatric autoimmune cytopenia
This study is trying to gather information about children with autoimmune blood disorders to see how they do over time and what treatments work best for them.
-
Evaluation of diagnosis and treatment for autoimmune cytopenias
This study is trying to understand how autoimmune cytopenias are diagnosed and treated, looking at different tests and treatments to see what works best for patients.
-
Biological bank for patients with autoimmune cytopenia
This study is setting up a collection of biological samples from patients with autoimmune cytopenia to help researchers learn more about these conditions and find better treatments.
-
F182112 in relapsed/refractory autoimmune hemolytic anemia
A small early study tests F182112 as a single treatment for adults with AIHA that has not responded to other therapies, to see if it’s safe and what dose works best.
-
Sirolimus added to standard therapy for adults with SLE-associated immune thrombocytopenia
This trial tests whether adding sirolimus to usual treatment helps adults with SLE-related immune thrombocytopenia see their platelet counts improve.
-
GL-2045 safety and blood-count help for adults with ITP
GL-2045 is being tested in adults with immune thrombocytopenia to see if it can safely raise platelet counts like IVIg does.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.